GlassScriptPhysician profile
Daljit S Bal
NPI 1144273533
$7,648.02
in general payments reported to CMS, 2019-2025
29 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $691 · 2021: $599 · 2022: $527 · 2023: $974 · 2024: $2,113 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,304.47 | 2019-2025 | |
| Janssen Biotech, INC. | $903.19 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $902.40 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $819.05 | 2019-2025 | Entyvio, Eohilia |
| Fujifilm Healthcare Americas Corporation | $695.84 | 2020-2021 | |
| Pfizer INC. | $610.82 | 2019-2025 | |
| Madrigal Pharmaceuticals | $391.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $370.06 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $290.48 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.98 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $166.00 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $108.12 | 2020-2024 | Talicia |
| Ferring Pharmaceuticals INC. | $96.03 | 2019-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $80.77 | 2024-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $77.38 | 2020-2024 | Advantage System, Solyx Sis System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.45 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $68.18 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $61.45 | 2023-2024 | Ibsrela |
| Shionogi INC | $56.21 | 2019-2020 | |
| Lucid Diagnostics INC. | $55.14 | 2023-2024 | |
| Celltrion USA INC. | $43.22 | 2024-2025 | Vegzelma |
| Daiichi Sankyo INC. | $40.59 | 2021 | |
| Ironwood Pharmaceuticals, INC | $31.35 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $28.92 | 2022 | |
| Echosens North America, INC. | $27.93 | 2019-2025 | Fibroscan |
| Fresenius Kabi USA, LLC | $27.32 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $17.79 | 2024 | Dificid |
| Allergan, INC. | $13.68 | 2019 | |
| Organon LLC | $5.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Bal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.